[12] Patent
[11] Patent No.:GC0007552  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125923
Date of the Decision to Grant the Patent:10/Apr/2018

[21] Application No.:GC 2010-17116

[22] Filing Date:22/11/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
20/11/2009
30/6/2010
61/263.137
61/359.914

[72] Inventors:1- Yuki Iwaki،2- Toshio Kawanami،3- Gary Michael Ksander،4- Muneto Mogi

[73] Owner: Novartis AG, Lichtstrasse 35, Basel 4056, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.7: [C07D231/40;C07D257/06;C07D261/14; A61K31/41; A61K31/42; A61K31/415 ;A61P7/10]

[56] Cited Documents:

-DE LOMBAERT S ET AL: Non-peptidic inhibitors of neutral endopeptidase 24.11 1. Discovery and optimization of potency, Bioorganic & Medicinal Chemistry letters, GB, 19 January 1995
-LOMBAERT DE S ET AL: dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides, Bioorganic & Medicinal Chemistry letters, GB, 01 January 1994
 
Examiner: PH. Sultana K. AlOudah

[54] SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS
[57] Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
No. of claims: 14


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.